目录肺癌文献更新2013年5月1LYMPHOMAPUBLICATIONALERTAUGUST2013淋巴瘤文献更新■本回复仅为学术交流之目的供中华人民共和国境内医学专业人士参考。医疗卫生专业人士做出的任何与治疗有关的决定应参考国家食品药品监督管理局批准的药品说明书；详见www.roche.com.cn未经授权，该资料不得翻印或散发。目录LYMPHOMAAUGUST20132CombinationofRituximabandtheMtorInhibitorEverolimus(RAD001)InDiffuseLargeBCellLymphoma.利妥昔单抗联用mTOR抑制剂依维莫司（RAD001）治疗弥漫性大B细胞淋巴瘤...........................................5Fludarabine-Mitoxantrone-RituximabRegimeninUntreatedIntermediate/High-RiskFollicularNon-Hodgkin'slymphoma:Experienceon142Patients.未接受过治疗中/高危滤泡性非霍奇金淋巴瘤的氟达拉滨+米托蒽醌联用利妥昔单抗治疗方案：来自142例患者的经验.............................................................................................................................................................6ThePrognosticImpactofAbsoluteLymphocyteandMonocyteCountsatDiagnosisofDiffuseLargeB-CellLymphomaintheRituximabEra.利妥昔单抗时代诊断弥漫性大B细胞淋巴瘤时淋巴细胞和单核细胞绝对计数的预后影响................................7EarlyStageFollicularLymphoma:WhatIsTheClinicalImpactofTheFirst-LineTreatmentStrategy?早期滤泡性淋巴瘤:一线治疗方案的临床疗效是什么?........................................................................................8OutcomesofPatientswithRelapsed/RefractoryDiffuseLargeB-CellLymphomawithProgressionofLymphomaafterAutologousStemCellTransplantationintheRituximabEra.在利妥昔单抗时代复发/难治性弥漫性大B细胞淋巴瘤患者进行自体干细胞移植后的疗效...............................9MYC/BCL2ProteinCoexpressionContributestoTheInferiorSurvivalofActivatedB-CellSubtypeofDiffuseLargeB-CellLymphomaandDemonstratesHigh-RiskGeneExpressionSignatures:AReportfromTheInternationalDLBCLRituximab-CHOPConsortiumProgram.MYC/BCL2蛋白共表达与弥漫性大B细胞淋巴瘤活性B细胞亚型的不良生存有关并可提示高危基因表达特征：一份来自国际DLBCL利妥昔单抗-CHOP联盟项目的报告......................................................................10Obinutuzumab(GA101)MonotherapyinRelapsed/RefractoryDiffuseLargeB-CellLymphomaorMantle-CellLymphoma:ResultsFromthePhaseIIGAUGUINStudy.复发/难治性弥漫性大B细胞淋巴瘤或套细胞淋巴瘤的Obinutuzumab（GA101）单药治疗:来自GAUGUIN研究的II期结果....................................................................................................................................................11ComparisonofOutcomesamongPatientsAged80andOverandYoungerPatientswithDiffuseLargeBCellLymphoma:APopulationBasedStudy.对年龄等于，小于和大于80周岁弥漫性大B淋巴瘤患者的疗效比较：一项基于人群的研究.........................12目录LYMPHOMAAUGUST20133EarlyTARCReductionandResponseFollowingPanobinostatTreatmentinPatientswithRelapsed/RefractoryHodgkinLymphomaFollowingAutologousStemCellTransplant.复发/难治性霍奇金淋巴瘤患者进行自体干细胞移植后接受帕比司他治疗后的早期TARC减少和缓解...........13IndicationsforHematopoieticStemCellTransplantationinPatientswithFollicularLymphoma:AConsensusProjectoftheEBMT-LymphomaWorkingParty.滤泡性淋巴瘤患者造血干细胞移植的标志:EBMT淋巴瘤工作组的一项共识项目...........................................14RecognizingNodalMarginalZoneLymphoma:RecentAdvancesandPitfalls.ASystematicReview.认识淋巴结边缘区淋巴瘤的最新进展和缺陷：一项系统性回顾....................................................................
VIP
